Phase II evaluation of thalidomide in patients with metastatic breast cancer

Said M. Baidas, Eric P. Winer, Gini F. Fleming, Lyndsay Harris, James M. Pluda, Jeanette G. Crawford, Hideko Yamauchi, Claudine Isaacs, John Hanfelt, Mariella Tefft, David Flockhart, Michael D. Johnson, Michael J. Hawkins, Marc E. Lippman, Daniel F. Hayes

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Purpose: To determine the efficacy, safety, pharmacokinetics, and effects on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer. Patients and Methods: Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 2000 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pre-treated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated. Results: No patients had a true partial or complete response. On the 800-mg arm, 13 patients had progressive disease at or before 8 weeks of treatment and one refused to continue treatment. The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for two and was increased for one to 1,000 mg and for four to 1,200 mg. On the 200-mg arm, 12 patients had progressive disease at or before 8 weeks and two had stable disease at 8 weeks, of whom one was removed from study at week 11 because of grade 3 neuropathy and the other had progressive disease at week 16. Dose-limiting toxicities included somnolence and neuropathy. Adverse events that did not require dose or schedule modifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia. Evaluation of circulating angiogenic factors and pharmacokinetic studies failed to provide insight into the reason for the lack of efficacy. Conclusion: Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer. Further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)2710-2717
Number of pages8
JournalJournal of Clinical Oncology
Volume18
Issue number14
StatePublished - Jul 2000
Externally publishedYes

Fingerprint

Thalidomide
Breast Neoplasms
Pharmacokinetics
Angiogenesis Inducing Agents
Intercellular Signaling Peptides and Proteins
Arm
Anorexia
Dizziness
Constipation
Exanthema
Neutropenia
Serum
Hypotension
Nausea
Fatigue
Headache
Mouth
Cardiac Arrhythmias
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baidas, S. M., Winer, E. P., Fleming, G. F., Harris, L., Pluda, J. M., Crawford, J. G., ... Hayes, D. F. (2000). Phase II evaluation of thalidomide in patients with metastatic breast cancer. Journal of Clinical Oncology, 18(14), 2710-2717.

Phase II evaluation of thalidomide in patients with metastatic breast cancer. / Baidas, Said M.; Winer, Eric P.; Fleming, Gini F.; Harris, Lyndsay; Pluda, James M.; Crawford, Jeanette G.; Yamauchi, Hideko; Isaacs, Claudine; Hanfelt, John; Tefft, Mariella; Flockhart, David; Johnson, Michael D.; Hawkins, Michael J.; Lippman, Marc E.; Hayes, Daniel F.

In: Journal of Clinical Oncology, Vol. 18, No. 14, 07.2000, p. 2710-2717.

Research output: Contribution to journalArticle

Baidas, SM, Winer, EP, Fleming, GF, Harris, L, Pluda, JM, Crawford, JG, Yamauchi, H, Isaacs, C, Hanfelt, J, Tefft, M, Flockhart, D, Johnson, MD, Hawkins, MJ, Lippman, ME & Hayes, DF 2000, 'Phase II evaluation of thalidomide in patients with metastatic breast cancer', Journal of Clinical Oncology, vol. 18, no. 14, pp. 2710-2717.
Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. Journal of Clinical Oncology. 2000 Jul;18(14):2710-2717.
Baidas, Said M. ; Winer, Eric P. ; Fleming, Gini F. ; Harris, Lyndsay ; Pluda, James M. ; Crawford, Jeanette G. ; Yamauchi, Hideko ; Isaacs, Claudine ; Hanfelt, John ; Tefft, Mariella ; Flockhart, David ; Johnson, Michael D. ; Hawkins, Michael J. ; Lippman, Marc E. ; Hayes, Daniel F. / Phase II evaluation of thalidomide in patients with metastatic breast cancer. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 14. pp. 2710-2717.
@article{3a9b50b65e8f4aa48a91a98013f12908,
title = "Phase II evaluation of thalidomide in patients with metastatic breast cancer",
abstract = "Purpose: To determine the efficacy, safety, pharmacokinetics, and effects on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer. Patients and Methods: Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 2000 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pre-treated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated. Results: No patients had a true partial or complete response. On the 800-mg arm, 13 patients had progressive disease at or before 8 weeks of treatment and one refused to continue treatment. The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for two and was increased for one to 1,000 mg and for four to 1,200 mg. On the 200-mg arm, 12 patients had progressive disease at or before 8 weeks and two had stable disease at 8 weeks, of whom one was removed from study at week 11 because of grade 3 neuropathy and the other had progressive disease at week 16. Dose-limiting toxicities included somnolence and neuropathy. Adverse events that did not require dose or schedule modifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia. Evaluation of circulating angiogenic factors and pharmacokinetic studies failed to provide insight into the reason for the lack of efficacy. Conclusion: Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer. Further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels. (C) 2000 by American Society of Clinical Oncology.",
author = "Baidas, {Said M.} and Winer, {Eric P.} and Fleming, {Gini F.} and Lyndsay Harris and Pluda, {James M.} and Crawford, {Jeanette G.} and Hideko Yamauchi and Claudine Isaacs and John Hanfelt and Mariella Tefft and David Flockhart and Johnson, {Michael D.} and Hawkins, {Michael J.} and Lippman, {Marc E.} and Hayes, {Daniel F.}",
year = "2000",
month = "7",
language = "English (US)",
volume = "18",
pages = "2710--2717",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Phase II evaluation of thalidomide in patients with metastatic breast cancer

AU - Baidas, Said M.

AU - Winer, Eric P.

AU - Fleming, Gini F.

AU - Harris, Lyndsay

AU - Pluda, James M.

AU - Crawford, Jeanette G.

AU - Yamauchi, Hideko

AU - Isaacs, Claudine

AU - Hanfelt, John

AU - Tefft, Mariella

AU - Flockhart, David

AU - Johnson, Michael D.

AU - Hawkins, Michael J.

AU - Lippman, Marc E.

AU - Hayes, Daniel F.

PY - 2000/7

Y1 - 2000/7

N2 - Purpose: To determine the efficacy, safety, pharmacokinetics, and effects on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer. Patients and Methods: Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 2000 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pre-treated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated. Results: No patients had a true partial or complete response. On the 800-mg arm, 13 patients had progressive disease at or before 8 weeks of treatment and one refused to continue treatment. The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for two and was increased for one to 1,000 mg and for four to 1,200 mg. On the 200-mg arm, 12 patients had progressive disease at or before 8 weeks and two had stable disease at 8 weeks, of whom one was removed from study at week 11 because of grade 3 neuropathy and the other had progressive disease at week 16. Dose-limiting toxicities included somnolence and neuropathy. Adverse events that did not require dose or schedule modifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia. Evaluation of circulating angiogenic factors and pharmacokinetic studies failed to provide insight into the reason for the lack of efficacy. Conclusion: Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer. Further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: To determine the efficacy, safety, pharmacokinetics, and effects on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer. Patients and Methods: Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 2000 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pre-treated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated. Results: No patients had a true partial or complete response. On the 800-mg arm, 13 patients had progressive disease at or before 8 weeks of treatment and one refused to continue treatment. The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for two and was increased for one to 1,000 mg and for four to 1,200 mg. On the 200-mg arm, 12 patients had progressive disease at or before 8 weeks and two had stable disease at 8 weeks, of whom one was removed from study at week 11 because of grade 3 neuropathy and the other had progressive disease at week 16. Dose-limiting toxicities included somnolence and neuropathy. Adverse events that did not require dose or schedule modifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia. Evaluation of circulating angiogenic factors and pharmacokinetic studies failed to provide insight into the reason for the lack of efficacy. Conclusion: Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer. Further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0033942084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033942084&partnerID=8YFLogxK

M3 - Article

C2 - 10894870

AN - SCOPUS:0033942084

VL - 18

SP - 2710

EP - 2717

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -